The company recently announced an acquisition that will bolster its growth prospects in the GLP-1 obesity market.Pfizer (PFE 0.32%)'s stock just can't seem to get out of a tailspin. It faces question marks about its future growth, and investors have effectively given up on it. Even though it looks like cheap stock to own, it continues to fall in value. Over the past 12 months, it's down 18% heading into trading this week. And over a five-year period, it has declined by 30%. There is, however, a compelling c ...